Influence of Sulphasalazine and Mesalazine on Cellular and Biochemical Oxygen Metabolite Production Effect of in vivo Administration and an in vitro Analysis

References

• Parks D A. Oxygen radicals: mediators of gastrointestinal pathophysiology. Gut 1989; 30: 293–298
   PubMed Web of Science ®Google Scholar
• Sava P, Blondeau C, Cubertafond P, Magnin P. Radicaux libres et pathologie digestive. Gastroenterol Clin Biol 1988; 12: 214–221
   PubMedGoogle Scholar
• Parks D A, Bulkley G B, Granger D N. Role of oxygen-derived free radicals in digestive tract diseases. Surgery 1983; 94: 415–422
   PubMed Web of Science ®Google Scholar
• Shandall A A, Williams G T, Hallett M B, Young H L. Colonic healing: a role for polymorphonuclear leucocytes and oxygen radical production. Br J Surg 1986; 73: 225–228
   PubMed Web of Science ®Google Scholar
• Grisham M B, Granger D N. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 1988; 33: 6S–15S
   PubMed Web of Science ®Google Scholar
• Keshavarzian A, Price Y E, Peters A M, et al. Specificity of indium-Ill granulocyte scanning and fecal excretion measurement in inflammatory bowel disease. An autoradiographic study. Dig Dis Sci 1985; 30: 1156–1160
   PubMed Web of Science ®Google Scholar
• Wandall J H, Binder V. Leucocyte function in Crohn's disease. Studies on mobilisation using a quantitative skin window technique and on the function of circulating polymorphonuclear leucocytes in vitro. Gut 1982; 23: 173–180
   PubMed Web of Science ®Google Scholar
• Wandall J H, Binder V. Leucocyte function in ulcerative colitis. Quantitative leucocyte mobilisation to skin windows and in vitro function of blood leucocytes. Gut 1982; 23: 758–765
   PubMed Web of Science ®Google Scholar
• Verspaget H W, Mieremet-Ooms M AC, Weterman I T, Pena A S. Partial defect of neutrophil oxidative metabolism of Crohn's disease. Gut 1984; 25: 849–853
   PubMed Web of Science ®Google Scholar
• Faden H, Rossi T M. Chemiluminescent response of neutrophils from patients with inflammatory bowel disease. Dig Dis Sci 1985; 30: 139–142
   PubMed Web of Science ®Google Scholar
• Verspaget H W, Elmgreen J, Weterman I T, Pena A S, Riis P, Lamers C BHW. Impaired activation of the neutrophil oxidative metabolism in chronic inflammatory bowel disease. Scand J Gastroenterol 1986; 21: 1124–1130
   PubMed Web of Science ®Google Scholar
• Suematsu M, Suzuki M, Kitahora T, et al. Increased respiratory burst of leukocytes in inflammatory bowel diseases—the analysis of free radical generation by using chemiluminescence probe. J Clin Lab Immunol 1987; 24: 125–128
   PubMedGoogle Scholar
• Verspaget H W, Pena A S, Weterman I T, Lamers C BHW. Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content. Gut 1988; 29: 223–228
   PubMed Web of Science ®Google Scholar
• Kitahora T, Suzuki K, Asakura H, et al. Active oxygen species generated by monocytes and polymorphonuclear cells in Crohn's disease. Dig Dis Sci 1988; 33: 951–955
   PubMed Web of Science ®Google Scholar
• Aruoma O I, Wasil M, Halliwell B, Hoey B M, Butler I. The scavenging of oxidants by sulphasalazine and its metabolites: a possible contribution to their antiinflammatory effect. Biochem Pharmacol 1987; 36: 3739–3742
   PubMed Web of Science ®Google Scholar
• Dull B J, Salata K, Van Langhove A, Goldman P. 5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage. Biochem Pharmacol 1987; 36: 2467–2472
   PubMed Web of Science ®Google Scholar
• Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987; 28: 190–195
   PubMed Web of Science ®Google Scholar
• Suematsu M, Suzuki M, Miura S, et al. Sulfasalazine and its metabolites attenuate respiratory burst of leukocytes. A possible mechanism of antiinflammatory effects. J Clin Lab Immunol 1987; 23: 31–33
   PubMedGoogle Scholar
• Williams J G, Hallett M B. The reaction of 5-amino-salicylic acid with hypochlorite. Implications for its mode of action in inflammatory bowel disease. Biochem Pharmacol 1989; 38: 149–154
   PubMed Web of Science ®Google Scholar
• Carlin G, Djursater R, Smedegard G. Inhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonuclear leukocytes. Pharmacol Toxicol 1989; 65: 121–127
   PubMedGoogle Scholar
• Dallegri F, Ottonello L, Ballestrero A, Bogliolo F, Ferrando F, Patrone F. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut 1990; 31: 184–186
   PubMed Web of Science ®Google Scholar
• Harvey R F, Bradshaw J M. A simple index of Crohn's disease activity. Lancet 1980; 1: 514
   PubMed Web of Science ®Google Scholar
• McCord J M, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969; 25: 6049–6055
   Google Scholar
• Hansson K A, Sandberg M. Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazo-sulphapyridine. Acta Pharm Suec 1973; 10: 87–92
   PubMedGoogle Scholar
• Shaw P N, Sivner A L, Aarons L, Houston J B. A rapid method of the simultaneous determination of the major metabolites of sulphasalazine in plasma. J Chrom Biomed App 1983; 274: 393–397
   PubMed Web of Science ®Google Scholar
• Bachrach W H. Sulfasalazine I. An historical perspective. Am J Gastroenterol 1988; 83: 487–496
   PubMed Web of Science ®Google Scholar
• Svartz N. Sulfasalazine. II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol 1988; 83: 497–503
   PubMed Web of Science ®Google Scholar
• Nielsen O H, Verspaget H W, Elmgreen J. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-amino-salicylic acid. Aliment Pharmacol Ther 1988; 2: 203–211
   PubMed Web of Science ®Google Scholar
• MacDermott R P, Kane M G, Steele L L, Stenson W F. Inhibition of cytotoxicity by sulfasalazine. I. Sulfasalazine inhibits spontaneous cell-mediated cytotoxicity by peripheral blood and intestinal mononuclear cells from controls and inflammatory bowel disease patients. Immunopharmacology 1986; 11: 101–109
   PubMedGoogle Scholar
• Shanahan F, Niederlehner A, MacDermott R P, Stenson W F, Kane M G, Targan S. Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes. Immunopharmacology 1986; 11: 111–118
   PubMed Web of Science ®Google Scholar
• Gibson P R, Jewell D P. Sulphasalazine and derivatives, natural killer cell activity and ulcerative colitis. Clin Sci 1985; 69: 177–184
   Web of Science ®Google Scholar
• Rampton D S, Sladen G E. Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. Prostaglandins 1981; 21: 417–425
   PubMed Web of Science ®Google Scholar
• Stenson W F, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 1982; 69: 494–498
   PubMed Web of Science ®Google Scholar
• Sharon P, Stenson W F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86: 453–460
   PubMed Web of Science ®Google Scholar
• Aparicio-Pagés M N, Verspaget H W, Hafkenscheid J CM, et al. Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity. Gut 1990; 31: 1030–1032
   PubMed Web of Science ®Google Scholar
• MacDermott R P, Schloemann S R, Bertovich M J, Nash G S, Peters M, Stenson W F. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology 1989; 96: 442–448
   PubMed Web of Science ®Google Scholar
• Stenson W F, Mehta J, Spilberg I. Sulfasalazine inhibition of binding of n-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem Pharmacol 1984; 33: 407–412
   PubMed Web of Science ®Google Scholar
• Allgayer H, Ahnfelt N O, Kruis W, et al. Colonic n-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989; 97: 38–41
   PubMed Web of Science ®Google Scholar